Dr. Kivitz has received consultant fees, speaking fees, and/or honoraria (less than $10,000) and research grants from Pfizer.
Twice Daily Versus Once Nightly Dosing of Pregabalin for Fibromyalgia: A Double-Blind Randomized Clinical Trial of Efficacy and Safety†
Article first published online: 28 JAN 2014
Copyright © 2014 by the American College of Rheumatology
Arthritis Care & Research
Volume 66, Issue 2, pages 293–300, February 2014
How to Cite
Nasser, K., Kivitz, A. J., Maricic, M. J., Silver, D. S. and Silverman, S. L. (2014), Twice Daily Versus Once Nightly Dosing of Pregabalin for Fibromyalgia: A Double-Blind Randomized Clinical Trial of Efficacy and Safety. Arthritis Care Res, 66: 293–300. doi: 10.1002/acr.22111
ClinicalTrials.gov identifier: NCT01226667.
- Issue published online: 28 JAN 2014
- Article first published online: 28 JAN 2014
- Accepted manuscript online: 27 AUG 2013 03:24PM EST
- Manuscript Accepted: 6 AUG 2013
- Manuscript Received: 16 APR 2013
Additional Supporting Information may be found in the online version of this article.
|ACR_22111_sm_SupplAppA.docx||14K||Supplementary Appendix A: study schedule of outcome questionnaires|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.